The mTOR Signalling Pathway: A Critical Review of Molecular Mechanism, Tissue-Specific Physiology and Clinical Translation

The mechanistic target of rapamycin (mTOR) is an atypical serine/threonine kinase of the phosphatidylinositol 3-kinase-related kinase family that couples nutrient and growth-factor availability to the decision between anabolism and catabolic recycling. Rather than cataloguing the field, this review is organised around a single argument: the therapeutic behaviour of mTOR-directed drugs is governed less by the potency with which they inhibit the kinase than by which complex is rate-limiting in which tissue, and most translational disappointments to date are explained by that distinction. We first summarise the molecular architecture of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), including recent structural work showing that mTORC2 selects Akt through distal docking on mSin1 some 75 Å from the catalytic site rather than through a local sequence motif. We then treat the lysosomal nutrient-sensing module, the growth-factor and energy inputs converging on TSC–Rheb, and the downstream output arms, explicitly separating findings that are well established from those that remain contested the relative physiological weight of the competing leucine-sensing mechanisms being the clearest example. A dedicated analysis of tissue-specific physiology shows that mTORC1 and mTORC2 have opposing consequences in liver, adipose tissue and pancreatic β-cells, which accounts mechanistically for hyperglycaemia, dyslipidaemia and new-onset diabetes during rapalog therapy, and predicts the therapeutic index of mTORC1-selective bi-steric agents. We add a treatment of circadian regulation of mTOR, absent from most pathway reviews, and update the clinical sections with the completed phase 1 trial of RMC-5552 and a critical appraisal of the PEARL, RTB101 and TRIIM studies. Human trials of mTOR inhibition differ so profoundly in population, compound selectivity, dose, schedule and endpoint that their apparently discordant results are largely reconcilable; we set out the specific design features a definitive geroscience trial would require. We conclude that partial, intermittent and complex-selective inhibition not maximal target engagement is the rational objective of mTOR pharmacology.

Authors

Institutions

Publication Details

Journal
Romanian Journal of Preventive Medicine
Published
2026-11-17
DOI
https://doi.org/10.3390/rjpm4040017
Primary Topic
PI3K/AKT/mTOR signaling in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The mTOR Signalling Pathway: A Critical Review of Molecular Mechanism, Tissue-Specific Physiology and Clinical Translation

Robert Jarema, Mikołaj Stańczak
Romanian Journal of Preventive Medicine
PI3K/AKT/mTOR signaling in cancer
article

The mTOR Signalling Pathway: A Critical Review of Molecular Mechanism, Tissue-Specific Physiology and Clinical Translation

Robert Jarema, Mikołaj Stańczak
article en

Abstract

The mechanistic target of rapamycin (mTOR) is an atypical serine/threonine kinase of the phosphatidylinositol 3-kinase-related kinase family that couples nutrient and growth-factor availability to the decision between anabolism and catabolic recycling. Rather than cataloguing the field, this review is organised around a single argument: the therapeutic behaviour of mTOR-directed drugs is governed less by the potency with which they inhibit the kinase than by which complex is rate-limiting in which tissue, and most translational disappointments to date are explained by that distinction. We first summarise the molecular architecture of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), including recent structural work showing that mTORC2 selects Akt through distal docking on mSin1 some 75 Å from the catalytic site rather than through a local sequence motif. We then treat the lysosomal nutrient-sensing module, the growth-factor and energy inputs converging on TSC–Rheb, and the downstream output arms, explicitly separating findings that are well established from those that remain contested the relative physiological weight of the competing leucine-sensing mechanisms being the clearest example. A dedicated analysis of tissue-specific physiology shows that mTORC1 and mTORC2 have opposing consequences in liver, adipose tissue and pancreatic β-cells, which accounts mechanistically for hyperglycaemia, dyslipidaemia and new-onset diabetes during rapalog therapy, and predicts the therapeutic index of mTORC1-selective bi-steric agents. We add a treatment of circadian regulation of mTOR, absent from most pathway reviews, and update the clinical sections with the completed phase 1 trial of RMC-5552 and a critical appraisal of the PEARL, RTB101 and TRIIM studies. Human trials of mTOR inhibition differ so profoundly in population, compound selectivity, dose, schedule and endpoint that their apparently discordant results are largely reconcilable; we set out the specific design features a definitive geroscience trial would require. We conclude that partial, intermittent and complex-selective inhibition not maximal target engagement is the rational objective of mTOR pharmacology.

Romanian Journal of Preventive MedicineVol. 4(4)
Medical University of Warsaw (PL), Heriot-Watt University (GB)
Good health and well-being
PI3K/AKT/mTOR signaling in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon